KILITCH DRUGS (INDIA) LTD.
NSE : KILITCHBSE : 524500ISIN
CODE : INE729D01010Industry : Pharmaceuticals & DrugsHouse
: Private
BSE350.85-4.8 (-1.35 % )
PREV CLOSE (Rs.) 355.65
OPEN PRICE (Rs.) 355.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 701
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE355.20 -1.65 (-0.46 % )
PREV CLOSE(Rs.) 356.85
OPEN PRICE (Rs.) 360.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 355.20 (15 )
VOLUME 3392
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 28-Feb-2024 | Kilitch Drugs (India) informs about issuance of duplicate share certificate | <p style="text-align: justify;">Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Kilitch Drugs (India) has informed that the Company has received intimation from the Registrar and Share Transfer Agents of the Company - Link Intime India for issue of duplicate share certificate as details enclosed. </p><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 27-Feb-2024 | PDS, Mahindra Finance and PNC Infratech to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">PDS</span>' subsidiary--- Norlanka Manufacturing India has proposed to acquire an equity stake of 5% in Frontier Knitters to expand apparel manufacturing footprint & leverage it to grow sourcing business. Cost of acquisition is Rs 1.02 crore. The said transaction is expected to be completed on or before April 30, 2024.</p><p style="text-align: justify;"><span style="font-weight: bold;">Mahindra & Mahindra Financial Services</span> (Mahindra Finance) has entered into partnership with Lendingkart. This co-lending partnership is set to provide business loans for the Small & Medium Enterprise (SME) sector and will boost Mahindra Finance's product diversification strategy, while fostering financial inclusion for small and medium enterprises.</p><p style="text-align: justify;"><span style="font-weight: bold;">PNC Infratech</span> has received Letter of Acceptance (LoA) from Madhya Pradesh Public Works Department (MPPWD) through Office of Chief Engineer, PWD Bridge Zone (Authority) on February 26, 2024 for the Project of Construction of Four Lane Elevated Corridor/Flyover from Maharani Laxmibai Pratima to A.B. Road (N.H. 46) Near Girwai Police Chouki on Swarn Rekha River in Gwalior City (2nd phase) in the state of Madhya Pradesh on EPC Mode. Broad Consideration or size of the order is Rs 699 crore along with GST as applicable. The said order is expected to be completed in 36 months (including rainy season). </p><p style="text-align: justify;"><span style="font-weight: bold;">Wipro </span>and Nokia have launched joint private wireless solution to help enterprises scale their digital transformation. This joint solution will provide enterprises with a more secure 5G private wireless network solution integrated with their operation infrastructure. The solution will bring greater reliability, mobility, connectivity speed, real-time access to business insights, and the ability to process high volumes of data with low latency. Through a dedicated wireless network, enterprises will be able to create an integrated private environment they can control to better manage their performance and mitigate security risks.</p><p style="text-align: justify;"><span style="font-weight: bold;">ITI </span>has signed Memorandums of Understandings (MoUs) with Lekha Wireless, Niral Networks and InstaICT Solution to create and manage entire Private 5G ecosystem for an enterprise, i.e. plan, design, deploy, implement and manage. The company has formalized a strategic collaboration with Lekha Wireless, Niral Networks, and InstaICT Solution aimed at driving the adoption of 5G technology in India. The MoUs signifies the beginning of a significant partnership between these niche entities in the telecommunications sector.</p><p style="text-align: justify;"><span style="font-weight: bold;">Kilitch Drug'</span>s subsidiary -- Kilitch Estro Biotech PLC has secured a significant tender issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia. This tender win marks a notable achievement for the company not only because of this tender but also it will definitely repeat as the Ethiopian Pharmaceutical Supply Service has planned to purchase injectable from local manufacturer.</p><p style="text-align: justify;"><span style="font-weight: bold;">Hind Rectifiers</span> has secured supply orders from Indian Railways. The orders are to be executed by FY2024-25. The broad consideration or size of the orders is more than Rs 200 crore. </p> |
| 26-Feb-2024 | Kilitch Drug's arm secures tender worth $9.13 million | <p style="text-align: justify;">Kilitch Drug's subsidiary -- Kilitch Estro Biotech PLC has secured a significant tender issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia. This tender win marks a notable achievement for the company not only because of this tender but also it will definitely repeat as the Ethiopian Pharmaceutical Supply Service has planned to purchase injectable from local manufacturer.</p><p style="text-align: justify;">The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to $9.13 million. The contract is executable within a timeline of six months from the receipt of the order, highlighting the efficiency and capability of the company's subsidiary in fulfilling such large-scale contracts. This accomplishment further solidifies the company's position in the pharmaceutical industry, showcasing its ability to secure substantial contracts and expand its presence in international markets. </p><p style="text-align: justify;">Kilitch Drugs (India) is an India-based company engaged in pharmaceutical business. The company's services range from manufacturing to marketing a host of formulations in all dosage forms, such as solid, liquid and parenteral forms. </p><div style="text-align: justify;"><br></div> |
| 17-Feb-2024 | Kilitch Drugs (India) informs about loss of share certificate | <p style="text-align: justify;">Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Kilitch Drugs (India) has informed that the Company has received intimation in relation with stop transfer due to loss of share certificate by shareholder -Sumit Kumar Mathur (Folio No: 0020738) from the Registrar and Share Transfer Agents of the Company - Link Intime India. Details of the share certificate are enclosed. </p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 18-Dec-2023 | Kilitch Drugs (India) informs about details of loss of certificate | <div style="text-align: justify;">Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Kilitch Drugs (India) has informed that the Company has received request for issuance of duplicate share certificate from the Registrar and Share Transfer Agents of the Company, Link intime India as details enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 22-Jul-2023 | Kilitch Drugs (India) informs about outcome of board meeting | <div style="text-align: justify;">Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Kilitch Drugs (India) has informed that the Board of Directors of the Company at its meeting held today i.e., Saturday, 22nd July, 2023 considered and approved the following; Obtaining credit facilities from bank not exceeding Rs 50,50,00,000 for the purpose of meeting day to day fund requirements of the Company. Conversion of 5,00,000 convertible warrants into 5,00,000 equity shares of face value of Rs 10 each of the Company out of the warrants allotted on 24th January, 2023 on preferential allotment basis to the allottees pursuant to exercise of their rights of conversion of warrants into equity shares and accordingly the Board of Directors have allotted 5,00,000 equity shares of face value of Rs 10 each fully paid up on account of conversion.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 17-Jul-2023 | Kilitch Drugs (India) informs about certificate | <p style="text-align: justify;">Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018, Kilitch Drugs (India) has informed that it enclosed the Certificate received from Link Intime India, the Registrar and Share Transfer Agent of the Company for the quarter ended 30th June, 2023.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 23-Jun-2023 | Kilitch Drugs (India) informs about loss of share certificate | <div style="text-align: justify;">Kilitch Drugs (India) has informed that the Company has received intimation in relation with loss of Share Certificate as attached from the Registrar and Share Transfer Agents of the Company, Link Intime India. </div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
